Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis
NAGOYA, Japan, June 30, 2026 /PRNewswire/ -- Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan; hereinafter "Kowa"), today announced that on June 11, it received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for "K-808" (development...
NAGOYA, Japan, June 30, 2026 /PRNewswire/ -- Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan; hereinafter "Kowa"), today announced that on June 11, it received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for "K-808" (development...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.